18FMNI 958

Drug Profile

18FMNI 958

Alternative Names: [18F]-MNI-958; APN-0000455; PM-PBB3

Latest Information Update: 08 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Molecular NeuroImaging
  • Class Diagnostic agents; Imaging agents; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers; Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Alzheimer's disease; Progressive supranuclear palsy

Most Recent Events

  • 12 Mar 2018 Phase-I clinical trials in Alzheimer's disease (Diagnosis) in USA (Injection) (NCT03545789)
  • 12 Mar 2018 Phase-I clinical trials in Progressive supranuclear palsy (Diagnosis) in USA (Injection) (NCT03545789)
  • 14 Nov 2017 Phase-I clinical trials in Healthy volunteers in USA (Injection) (NCT03472313)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top